Clinical Chemistry Analyzers Market by Product (Fully-Automated Analyzers, PoC Analyzers, Reagents), Test Type (Basic Metabolic, Liver, Renal, Lipid, Thyroid Function), End User (Hospitals, Clinics, Laboratories, Research) & Region - Global Forecasts to 2026
The global clinical chemistry analyzers market in terms of revenue was estimated to be worth $12.3 billion in 2021 and is poised to reach $15.2 billion by 2026, growing at a CAGR of 4.3% from 2021 to 2026. Market growth is driven by the rising geriatric population and the increasing prevalence of chronic & lifestyle diseases, growing adoption of Point-of-Care testing devices and rising demand for laboratory automation.
To know about the assumptions considered for the study, Request for Free Sample Report
Clinical Chemistry Analyzer Market Dynamics
Drivers: Rising geriatric population and the increasing prevalence of chronic & lifestyle diseases
The rising geriatric population in developed and developing regions will positively influence the growth of the clinical chemistry analyzers market. Due to rapid growth in the senior population, the prevalence of age-associated diseases such as hypertension, diabetes, cardiovascular, liver, and kidney diseases are expected to increase significantly. The diagnosis and management of such diseases are responsible for the increasing number of prescriptions for tests such as basic metabolic panel, lipid profile, and liver & renal panel.The rise in chronic illnesses will increase the demand for tests prescribed for the prevention, diagnosis, and treatment for the same. These factors, alongside the growing trend for preventive medicine, is expected to drive the demand for clinical chemistry analyzers during the forecast period. These tests are performed by clinical chemistry analyzers; hence, it is expected to have a positive impact on this market.
Opportunities: Increasing government initiatives and funding for preventive care
The government initiatives, schemes, or funding that supports and promotes the innovation and development of the diagnostics market provides growth opportunities in the clinical chemical analyzers market.
Restraints: The requirement of high capital investments and a shortage of skilled laboratory technicians
The high-volume clinical chemistry analyzers may be affordable only for large hospitals and reference laboratories with good capital budgets. Most small laboratories, physician’s offices, and sole practitioners have no capital budgets and may not be able to afford a large or very large-sized analyzer. Thus, the high fixed-cost requirements limit the growth of the global market.
At present, there is a significant shortage of laboratory technicians in both developed and developing nations. This is mainly attributed to the increasing patient population base, the retirement of elderly technicians, and the increasing number of cash-strapped colleges closing their clinical lab programs. Thus, there is a gap between the supply and demand of pathologists and lab technicians worldwide, therefore expecting to restrain the market growth.
Reagents segment accounted for the largest share of the market, by product
Based on product, the global market is segmented into analyzers, reagents and other products. The reagents segment accounted for the largest share in this market in 2020. The recurrent requirement of reagents in large numbers as compared to analyzers is the major factor driving the growth of this segment.
Basic metabolic panel tests segment accounted for the largest share in the market, by test type
The global market is segmented into basic metabolic panels, electrolyte panels, liver panels, lipid profiles, renal profiles, thyroid function panels, and specialty chemical tests based on test type. In 2020, the basic metabolic panel tests segment accounted for the largest share. This can be attributed to the rising incidence of diabetes and other lifestyle & chronic diseases and the increasing trend of preventive healthcare.
North America is the largest regional market for clinical chemistry analyzers
The global clinical chemistry analyzers market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America accounted for the largest share of the global market. The North American market's growth can be attributed to the increasing geriatric population, increasing prevalence of chronic & lifestyle conditions, implementation of favorable government initiatives, increasing healthcare expenditure, improved healthcare infrastructure, and the availability of technologically advanced instruments.
The major players operating in this market are F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), Abbott Laboratories (US), Thermo Fisher Scientific Inc. (US), Siemens AG (Germany), HORIBA Ltd. (Japan), Sysmex Corporation (Japan), HITACHI (Japan), EKF Diagnostics (UK), Ortho Clinical Diagnostics (US), ELITech Group (France), Mindray Medical International Ltd. (China), BIOBASE Group (China), SFRI Medical Diagnostics (France), Trivitron Healthcare Pvt. Ltd. (India), Randox Laboratories Ltd. (UK), among others.
Get online access to the report on the World's First Market Intelligence Cloud
- Easy to Download Historical Data & Forecast Numbers
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
Request Sample Scope of the Report
Get online access to the report on the World's First Market Intelligence Cloud
- Easy to Download Historical Data & Forecast Numbers
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
|
Report Metric |
Details |
|
Market size available for years |
2019–2026 |
|
Base year considered |
2020 |
|
Forecast period |
2021–2026 |
|
Forecast units |
Value (USD Billion) |
|
Segments covered |
Product, test type, end user, and region |
|
Geographies covered |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
|
Companies covered |
F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), Abbott Laboratories (US), Thermo Fisher Scientific Inc. (US), Siemens AG (Germany), HORIBA Ltd. (Japan), Sysmex Corporation (Japan), HITACHI (Japan), EKF Diagnostics (UK), Ortho Clinical Diagnostics (US), ELITech Group (France), Mindray Medical International Ltd. (China), BIOBASE Group (China), SFRI Medical Diagnostics (France), Trivitron Healthcare Pvt. Ltd. (India), Randox Laboratories Ltd. (UK), Medica Corporation (US), Meril Life Sciences Pvt. Ltd. (India), Erba Mannheim (UK), Genrui Biotech Inc. (China), DIRUI Industrial Co. Ltd. (China), Teco Diagnostics (US), Balio Diagnostics (France), Snibe Co. Ltd. (China), and AMS Alliance (Italy) |
This report categorizes the clinical chemistry analyzers market into the following segments and sub-segments:
By Product
- Reagents
- Analyzers
- Other Products
By Test Type
- Basic Metabolic Panels
- Liver Panels
- Renal Panels
- Lipid Profiles
- Thyroid Function Panels
- Electrolyte Panels
- Specialty Chemical Tests
By End User
- Hospitals and Clinics
- Diagnostic Laboratories
- Research Laboratories & Institutes
- Other End Users
By Region
-
North America
- US
- Canada
-
Europe
- UK
- Germany
- France
- Italy
- Spain
- Russia
- Rest of Europe (RoE)
-
Asia Pacific
- China
- Japan
- India
- Rest of Asia Pacific (RoAPAC)
- Latin America
- Middle East & Africa
Recent Developments
- In January 2020, Sysmex invested in Astrego Diagnostics for the development of urinalysis solutions.
- In November 2017, Roche Diagnostics acquired Viewics (US) to expand its leading position in the integrated core lab space with business analytics capabilities.
- In December 2018, BIOBASE Group launched BK200 mini auto chemistry analyzer for small laboratories and clinics to meet the needs of its customers.
Frequently Asked Questions (FAQs):
What is the size of Clinical Chemistry Analyzers Market?
The global Clinical Chemistry Analyzers Market size is projected to reach USD 15.2 billion by 2026, growing at a CAGR of 4.3%.
What are the major growth factors of Clinical Chemistry Analyzers Market?
Market growth is driven by the rising geriatric population and the increasing prevalence of chronic & lifestyle diseases, growing adoption of Point-of-Care testing devices and rising demand for laboratory automation.
Who all are the prominent players of Clinical Chemistry Analyzers Market?
The major players operating in this market are F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), Abbott Laboratories (US), Thermo Fisher Scientific Inc. (US), Siemens AG (Germany), HORIBA Ltd. (Japan), Sysmex Corporation (Japan), HITACHI (Japan), EKF Diagnostics (UK), Ortho Clinical Diagnostics (US), ELITech Group (France), Mindray Medical International Ltd. (China), BIOBASE Group (China), SFRI Medical Diagnostics (France), Trivitron Healthcare Pvt. Ltd. (India), Randox Laboratories Ltd. (UK), Medica Corporation (US), Meril Life Sciences Pvt. Ltd. (India), Erba Mannheim (UK), Genrui Biotech Inc. (China), DIRUI Industrial Co. Ltd. (China), Teco Diagnostics (US), Balio Diagnostics (France), Snibe Co. Ltd. (China), and AMS Alliance (Italy).
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 24)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
FIGURE 1 INCLUSIONS & EXCLUSIONS
1.2.1 MARKETS COVERED
FIGURE 2 CLINICAL CHEMISTRY ANALYZERS MARKET
1.2.2 YEARS CONSIDERED FOR THE STUDY
1.3 CURRENCY
1.4 LIMITATIONS
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 29)
2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
FIGURE 3 GLOBAL MARKET: RESEARCH DESIGN METHODOLOGY
2.2.1 SECONDARY DATA
2.2.1.1 Key data from secondary sources
2.2.2 PRIMARY DATA
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2.2.1 Key data from primary sources
2.3 MARKET SIZE ESTIMATION
2.3.1 BOTTOM-UP APPROACH
FIGURE 5 GLOBAL MARKET: BOTTOM-UP APPROACH
2.3.2 TOP-DOWN APPROACH
FIGURE 6 CLINICAL CHEMISTRY ANALYZER MARKET: TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 7 DATA TRIANGULATION METHODOLOGY
2.5 ASSUMPTIONS FOR THE STUDY
3 EXECUTIVE SUMMARY (Page No. - 38)
FIGURE 8 GLOBAL MARKET, BY PRODUCT, 2021 VS. 2026 (USD MILLION)
FIGURE 9 GLOBAL MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION)
FIGURE 10 GLOBAL MARKET, BY TEST TYPE, 2021 VS. 2026 (USD MILLION)
FIGURE 11 GLOBAL MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
FIGURE 12 GLOBAL MARKET, BY REGION, 2021 VS. 2026 (USD MILLION)
4 PREMIUM INSIGHTS (Page No. - 42)
4.1 GLOBAL MARKET OVERVIEW
FIGURE 13 THE RISING ADOPTION OF POC PRODUCTS IS EXPECTED TO SUPPORT MARKET GROWTH DURING THE FORECAST PERIOD
4.2 GLOBAL MARKET, BY PRODUCT, 2021 VS. 2026 (USD MILLION)
FIGURE 14 THE REAGENTS SEGMENT IS EXPECTED TO COMMAND THE LARGEST SHARE OF THE MARKET, BY PRODUCT, IN 2021
4.3 GLOBAL MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION)
FIGURE 15 THE SEMI-AUTOMATIC ANALYZER SEGMENT IS EXPECTED TO HOLD THE LARGEST SHARE OF THE MARKET, BY TYPE, DURING THE FORECAST PERIOD
4.4 GLOBAL MARKET, BY REGION, 2021 VS. 2026
FIGURE 16 THE ASIA PACIFIC MARKET IS ESTIMATED TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 45)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 17 CLINICAL CHEMISTRY ANALYZER MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND TRENDS
5.2.1 DRIVERS
5.2.1.1 Rising geriatric population and the increasing prevalence of chronic & lifestyle diseases
TABLE 1 ESTIMATED INCREASE IN THE GERIATRIC POPULATION, BY REGION (2019-2050)
5.2.1.2 Growing adoption of Point-of-Care testing devices
5.2.1.3 Increasing demand for laboratory automation
5.2.2 RESTRAINTS
5.2.2.1 The requirement of high capital investments and a shortage of skilled laboratory technicians
5.2.2.2 Availability of refurbished analyzers
5.2.3 OPPORTUNITIES
5.2.3.1 Increasing government initiatives and funding for preventive care
5.2.4 TRENDS
5.2.4.1 Multichannel operations of integrated analyzers
5.2.5 COVID 19 IMPACT ANALYSIS
5.3 PRICING ANALYSIS
TABLE 2 AVERAGE SELLING PRICES OF PRODUCTS (USD)
5.4 VALUE CHAIN ANALYSIS
FIGURE 18 VALUE CHAIN ANALYSIS OF THE GLOBAL MARKET
5.5 PATENT ANALYSIS
5.6 SUPPLY CHAIN ANALYSIS
FIGURE 19 SUPPLY CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS
5.8 REGULATORY LANDSCAPE
5.8.1 NORTH AMERICA
5.8.1.1 US
5.8.1.2 Canada
5.8.2 EUROPE
5.8.3 ASIA PACIFIC
5.8.3.1 China
5.8.3.2 Japan
5.8.3.3 India
5.8.4 LATIN AMERICA
5.8.4.1 Brazil
5.8.4.2 Mexico
5.8.5 MIDDLE EAST
5.8.6 AFRICA
5.9 PORTER’S FIVE FORCES ANALYSIS
FIGURE 20 PORTER’S FIVE FORCES ANALYSIS
5.9.1 THREAT FROM NEW ENTRANTS
5.9.2 THREAT FROM SUBSTITUTES
5.9.3 BARGAINING POWER OF BUYERS
5.9.4 BARGAINING POWER OF SUPPLIERS
5.9.5 COMPETITIVE RIVALRY AMONG EXISTING PLAYERS
5.10 PESTLE ANALYSIS
5.11 TRADE ANALYSIS
5.11.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
TABLE 3 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2016-2020 (USD MILLION)
6 CLINICAL CHEMISTRY ANALYZERS MARKET, BY PRODUCT (Page No. - 61)
6.1 INTRODUCTION
TABLE 4 CLINICAL CHEMISTRY REAGENTS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
6.2 REAGENTS
6.2.1 THE RECURRENT PURCHASE REQUIREMENT OF REAGENTS DRIVES MARKET GROWTH
TABLE 5 CLINICAL CHEMISTRY REAGENTS MARKET, BY REGION, 2019–2026 (USD MILLION)
6.3 ANALYZERS
TABLE 6 GLOBAL MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 7 GLOBAL MARKET, BY REGION, 2019–2026 (USD MILLION)
6.3.1 SEMI-AUTOMATIC ANALYZERS
6.3.1.1 The cost-effectiveness of semi-automatic analyzers drives segment growth
TABLE 8 SEMI-AUTOMATIC ANALYZERS MARKET, BY REGION, 2019–2026 (USD MILLION)
6.3.2 FULLY AUTOMATIC ANALYZERS
6.3.2.1 Fully automatic analyzers offer rapid sample processing, thus enhancing workflows
TABLE 9 FULLY AUTOMATIC ANALYZERS MARKET, BY REGION, 2019–2026 (USD MILLION)
6.3.3 POINT-OF-CARE ANALYZERS
6.3.3.1 The increasing adoption of PoC technologies drives segment growth
TABLE 10 POINT-OF-CARE ANALYZERS MARKET, BY REGION, 2019–2026 (USD MILLION)
6.4 OTHER PRODUCTS
TABLE 11 CLINICAL CHEMISTRY ANALYZERS FOR OTHER PRODUCTS MARKET, BY REGION, 2019–2026 (USD MILLION)
7 CLINICAL CHEMISTRY ANALYZERS MARKET, BY TEST TYPE (Page No. - 67)
7.1 INTRODUCTION
TABLE 12 GLOBAL MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)
7.2 BASIC METABOLIC PANEL
7.2.1 THE RISING INCIDENCE OF DIABETES AND OTHER CHRONIC DISEASES IS A PRIMARY GROWTH DRIVER FOR THIS SEGMENT
TABLE 13 BASIC METABOLIC PANEL TESTS MARKET, BY REGION, 2019–2026 (USD MILLION)
7.3 LIVER PANEL
7.3.1 THE INCREASING INCIDENCE OF LIVER-RELATED DISEASES IS A KEY FACTOR DRIVING MARKET GROWTH
TABLE 14 LIVER PANEL TESTS MARKET, BY REGION, 2019–2026 (USD MILLION)
7.4 RENAL PROFILE
7.4.1 THE RISING INCIDENCE OF ESRD PATIENTS DRIVES THE GROWTH OF THE RENAL PROFILE TESTING MARKET
TABLE 15 RENAL PROFILE TESTS MARKET, BY REGION, 2019–2026 (USD MILLION)
7.5 LIPID PROFILE
7.5.1 LIPID PROFILE TESTS ARE PRESCRIBED TO MONITOR UNHEALTHY LIPID LEVELS AND AVOID CVD RISKS
TABLE 16 LIPID PROFILE TESTS MARKET, BY REGION, 2019–2026 (USD MILLION)
7.6 THYROID FUNCTION PANEL
7.6.1 THE INCREASING INCIDENCE OF THYROID-RELATED DISORDERS DRIVES THE GROWTH OF THIS SEGMENT
TABLE 17 THYROID FUNCTION PANEL TESTS MARKET, BY REGION, 2019–2026 (USD MILLION)
7.7 ELECTROLYTE PANEL
7.7.1 THE ELECTROLYTE TEST PANEL IS PRESCRIBED TO PATIENTS THAT SUFFER FROM HYPERTENSION OR LIVER & KIDNEY DISEASES
TABLE 18 ELECTROLYTE PANEL TESTS MARKET, BY REGION, 2019–2026 (USD MILLION)
7.8 SPECIALTY CHEMICAL TESTS
7.8.1 THIS SEGMENT IS EXPECTED TO GROW AT THE LOWEST CAGR DURING THE FORECAST PERIOD AS THESE TESTS ARE NOT PRESCRIBED REGULARLY
TABLE 19 SPECIALTY CHEMICAL TESTS MARKET, BY REGION, 2019–2026 (USD MILLION)
8 CLINICAL CHEMISTRY ANALYZERS MARKET, BY END USER (Page No. - 75)
8.1 INTRODUCTION
TABLE 20 GLOBAL MARKET, BY END USER, 2019–2026 (USD MILLION)
8.2 HOSPITALS AND CLINICS
8.2.1 HOSPITALS ARE THE MAJOR END USERS OF CLINICAL CHEMISTRY ANALYZERS
TABLE 21 GLOBAL MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2019–2026 (USD MILLION)
8.3 DIAGNOSTIC LABORATORIES
8.3.1 INCREASING OUTSOURCING ACTIVITIES TO DIAGNOSTIC LABORATORIES FOR REDUCED COSTS DRIVE THE GROWTH OF THIS SEGMENT
TABLE 22 GLOBAL MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2019–2026 (USD MILLION)
8.4 RESEARCH LABORATORIES & INSTITUTES
8.4.1 GROWTH IN FUNDING FOR LIFE SCIENCE RESEARCH IS A PRIMARY DRIVER FOR THIS END-USER SEGMENT
TABLE 23 GLOBAL MARKET FOR RESEARCH LABORATORIES & INSTITUTES, BY REGION, 2019–2026 (USD MILLION)
8.5 OTHER END USERS
TABLE 24 GLOBAL MARKET FOR OTHER END USERS,BY REGION, 2019–2026 (USD MILLION)
9 CLINICAL CHEMISTRY ANALYZERS MARKET, BY REGION (Page No. - 80)
9.1 INTRODUCTION
TABLE 25 GLOBAL MARKET, BY REGION, 2019–2026 (USD MILLION)
9.2 NORTH AMERICA
FIGURE 21 NORTH AMERICA: MARKET SNAPSHOT
TABLE 26 NORTH AMERICA: MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 27 NORTH AMERICA: MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 28 NORTH AMERICA: MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 29 NORTH AMERICA: MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)
TABLE 30 NORTH AMERICA: MARKET, BY END USER, 2019–2026 (USD MILLION)
9.2.1 US
9.2.1.1 Increasing cases of diabetes & obesity-related diseases is a key factor expected to drive market growth
TABLE 31 US: CLINICAL CHEMISTRY ANALYZERS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 32 US: MARKET, BY TYPE,2019–2026 (USD MILLION)
TABLE 33 US: MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)
TABLE 34 US: MARKET, BY END USER, 2019–2026 (USD MILLION)
9.2.2 CANADA
9.2.2.1 The increasing prevalence of chronic & lifestyle diseases drives the market growth in Canada
TABLE 35 CANADA: MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 36 CANADA: MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 37 CANADA: MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)
TABLE 38 CANADA: MARKET, BY END USER2019–2026 (USD MILLION)
9.3 EUROPE
TABLE 39 EUROPE: MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 40 EUROPE: MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 41 EUROPE: MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 42 EUROPE: MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)
TABLE 43 EUROPE: MARKET, BY END USER, 2019–2026 (USD MILLION)
9.3.1 UK
9.3.1.1 The increasing number of accredited clinical laboratories in the UK propels market growth for chemical analyzers
TABLE 44 UK: MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 45 UK: MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 46 UK: MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)
TABLE 47 UK: MARKET, BY END USER, 2019–2026 (USD MILLION)
9.3.2 GERMANY
9.3.2.1 Increasing healthcare expenditure to drive market growth in Germany
TABLE 48 GERMANY: CLINICAL CHEMISTRY ANALYZERS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 49 GERMANY: MARKET, BY TYPE,2019–2026 (USD MILLION)
TABLE 50 GERMANY: MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)
TABLE 51 GERMANY: MARKET, BY END USER, 2019–2026 (USD MILLION)
9.3.3 FRANCE
9.3.3.1 Rising R&D expenditure in France to drive market growth
TABLE 52 FRANCE: MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 53 FRANCE: MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 54 FRANCE: MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)
TABLE 55 FRANCE: MARKET, BY END USER, 2019–2026 (USD MILLION)
9.3.4 ITALY
9.3.4.1 Age-related chronic conditions owing to a large geriatric population to drive market growth in Italy
TABLE 56 ITALY: MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 57 ITALY: MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 58 ITALY: MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)
TABLE 59 ITALY: MARKET, BY END USER, 2019–2026 (USD MILLION)
9.3.5 SPAIN
9.3.5.1 Increasing prevalence of age-associated disorders to drive market growth in Spain
TABLE 60 SPAIN: MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 61 SPAIN: MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 62 SPAIN: MARKET, BY TEST TYPE,2019–2026 (USD MILLION)
TABLE 63 SPAIN: MARKET, BY END USER, 2019–2026 (USD MILLION)
9.3.6 RUSSIA
9.3.6.1 Increasing access to quality healthcare will support market growth in Russia
TABLE 64 RUSSIA: CLINICAL CHEMISTRY ANALYZERS MARKET, BY PRODUCT,2019–2026 (USD MILLION)
TABLE 65 RUSSIA: MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 66 RUSSIA: MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)
TABLE 67 RUSSIA: MARKET, BY END USER, 2019–2026 (USD MILLION)
9.3.7 REST OF EUROPE (ROE)
TABLE 68 ROE: MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 69 ROE: MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 70 ROE: MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)
TABLE 71 ROE: MARKET, BY END USER, 2019–2026 (USD MILLION)
9.4 ASIA PACIFIC
FIGURE 22 APAC: MARKET SNAPSHOT
TABLE 72 APAC: MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 73 APAC: MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 74 APAC: MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 75 APAC: MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)
TABLE 76 APAC: MARKET, BY END USER, 2019–2026 (USD MILLION)
9.4.1 CHINA
9.4.1.1 China accounted for the largest share of the APAC market in 2020
TABLE 77 CHINA: CLINICAL CHEMISTRY ANALYZERS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 78 CHINA: MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 79 CHINA: MARKET, BY TEST TYPE,2019–2026 (USD MILLION)
TABLE 80 CHINA: MARKET, BY END USER, 2019–2026 (USD MILLION)
9.4.2 JAPAN
9.4.2.1 A favorable regulatory framework to drive market growth in Japan
TABLE 81 JAPAN: MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 82 JAPAN: MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 83 JAPAN: MARKET, BY TEST TYPE,2019–2026 (USD MILLION)
TABLE 84 JAPAN: MARKET, BY END USER, 2019–2026 (USD MILLION)
9.4.3 INDIA
9.4.3.1 Increasing private & public investments in the country’s healthcare system will drive market growth
TABLE 85 INDIA: MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 86 INDIA: MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 87 INDIA: MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)
TABLE 88 INDIA: MARKET, BY END USER, 2019–2026 (USD MILLION)
9.4.4 REST OF ASIA PACIFIC (ROAPAC)
TABLE 89 ROAPAC: MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 90 ROAPAC: MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 91 ROAPAC: MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)
TABLE 92 ROAPAC: MARKET, BY END USER, 2019–2026 (USD MILLION)
9.5 LATIN AMERICA
TABLE 93 LATIN AMERICA: CLINICAL CHEMISTRY ANALYZERS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 94 LATIN AMERICA: MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 95 LATIN AMERICA: MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)
TABLE 96 LATIN AMERICA: MARKET, BY END USER, 2019–2026 (USD MILLION)
9.6 MIDDLE EAST AND AFRICA
TABLE 97 MEA: MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 98 MEA: MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 99 MEA: MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)
TABLE 100 MEA: MARKET, BY END USER, 2019–2026 (USD MILLION)
10 COMPETITIVE LANDSCAPE (Page No. - 118)
10.1 OVERVIEW
FIGURE 23 KEY DEVELOPMENTS IN THE CLINICAL CHEMISTRY ANALYZERS MARKET
10.2 MARKET SHARE ANALYSIS
FIGURE 24 GLOBAL MARKET SHARE, BY KEY PLAYER (2019)
10.3 COMPANY EVALUATION QUADRANT
10.3.1 LIST OF EVALUATED VENDORS
10.3.2 STARS
10.3.3 EMERGING LEADERS
10.3.4 PERVASIVE PLAYERS
10.3.5 PARTICIPANTS
FIGURE 25 GLOBAL MARKET: COMPETITIVE LEADERSHIP MAPPING, 2019
10.4 COMPETITIVE EVALUATION MATRIX FOR START-UPS (2019)
10.4.1 PROGRESSIVE COMPANIES
10.4.2 STARTING BLOCKS
10.4.3 RESPONSIVE COMPANIES
10.4.4 DYNAMIC COMPANIES
FIGURE 26 GLOBAL MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS, 2019
10.5 COMPETITIVE SCENARIO
10.5.1 MARKET EVALUATION MATRIX, 2018-2020
FIGURE 27 MARKET EVALUATION MATRIX, 2018-2020
10.5.2 PRODUCT LAUNCHES
TABLE 101 KEY PRODUCT LAUNCHES
10.5.3 ACQUISITIONS
TABLE 102 KEY ACQUISITIONS
10.5.4 PARTNERSHIPS, AGREEMENTS, AND COLLABORATIONS
TABLE 103 KEY PARTNERSHIPS, AGREEMENTS, AND COLLABORATIONS
10.5.5 EXPANSIONS
TABLE 104 KEY EXPANSIONS
11 COMPANY PROFILES (Page No. - 127)
(Business Overview, Products Offered, Recent Developments, and MnM View)*
11.1 ROCHE DIAGNOSTICS LTD.
FIGURE 28 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2019)
11.2 DANAHER CORPORATION
FIGURE 29 DANAHER CORPORATION: COMPANY SNAPSHOT (2019)
11.3 ABBOTT LABORATORIES
FIGURE 30 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2019)
11.4 THERMO FISHER SCIENTIFIC INC.
FIGURE 31 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2019)
11.5 SIEMENS HEALTHINEERS AG
FIGURE 32 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT
11.6 HORIBA, LTD.
FIGURE 33 HORIBA LTD.: COMPANY SNAPSHOT (2019)
11.7 SYSMEX CORPORATION
FIGURE 34 SYSMEX CORPORATION: COMPANY SNAPSHOT (2019)
11.8 EKF DIAGNOSTICS
FIGURE 35 EKF DIAGNOSTICS: COMPANY SNAPSHOT
11.9 HITACHI
FIGURE 36 HITACHI LTD.: COMPANY SNAPSHOT (2019)
11.10 ORTHO CLINICAL DIAGNOSTICS
11.11 ELITECHGROUP
11.12 MINDRAY MEDICAL INTERNATIONAL LTD.
11.13 BIOBASE GROUP
11.14 SFRI MEDICAL DIAGNOSTICS
11.15 TRIVITRON HEALTHCARE PVT. LTD.
11.16 RANDOX LABORATORIES LTD.
11.17 MEDICA CORPORATION
11.18 MERIL LIFE SCIENCES PVT. LTD.
11.19 ERBA MANNHEIM
11.20 GENRUI BIOTECH INC.
11.21 DIRUI INDUSTRIAL CO., LTD.
11.22 TECO DIAGNOSTICS
11.23 BALIO DIAGNOSTICS
11.24 SNIBE CO. LTD.
11.25 AMS ALLIANCE
*Details on Business Overview, Products Offered, Recent Developments, and MnM View might not be captured in case of unlisted companies.
12 APPENDIX (Page No. - 158)
12.1 INSIGHTS FROM INDUSTRY EXPERTS
12.2 DISCUSSION GUIDE
12.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.4 AVAILABLE CUSTOMIZATIONS
12.5 RELATED REPORTS
12.6 AUTHOR DETAILS
This study involved four major activities in estimating the current size of the clinical chemistry analyzers market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate segments and subsegments' market size.
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.
Primary Research
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects.
The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study,download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the clinical chemistry analyzers market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry have been identified through extensive secondary research
- The revenues generated by leading players operating in the global market have been determined through primary and secondary research
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources
Global Clinical Chemistry Analyzers Market Size: Top-Down Approach
Data Triangulation
After arriving at the overall market size applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Report Objectives
- To define, describe, segment, and forecast the global clinical chemistry analyzers market by product, test type, end user, and region
- To provide detailed information regarding the major factors influencing the market growth (drivers, restraints, opportunities, and trends)
- To analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the market segments with respect to five regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies2
- To track and analyze company developments such as product launches, partnerships, expansions, and acquisitions in the clinical chemistry analyzers market
- To benchmark players within the market using the proprietary "Competitive Leadership Mapping" framework, which analyzes market players on various parameters within the broad categories of business and product strategy
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:
Country Information
- Clinical Chemistry Analyzers market size and growth rate estimates for countries in the Rest of Europe, the Rest of Asia Pacific, Latin America, and Middle East & Africa
Company profiles
- Additional fifteen company profiles of players operating in the clinical chemistry analyzers market
Growth opportunities and latent adjacency in Clinical Chemistry Analyzers Market